Frank Pasqualone
CIK 1597334 · SVP, CHIEF BUSINESS OFFICER · last filed 2026-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TBPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
245 FIRST ST, RIVERVIEW II, 18TH FLOOR
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ENVB | Director | 26,423 | $1.40 | $37.0K | $2.1K | 4 | 2026-06-03 |
| Theravance Biopharma, Inc. (TBPH) Delisted | SVP, CHIEF BUSINESS OFFICER | 429,783 | $17.03 | $7.32M | $105.4K | 30 | 2021-11-23 |
| Innoviva, Inc. (THRX) Delisted | Sr. Vice President, Operations | 20,000 | $4.06 | $81.2K | $0 | 1 | 2014-01-27 |
Recent Filings · Page 3 of 4
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-08-22 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −5,735 | -$154.6K | EDGAR |
| 2018-05-22 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −18,424 | -$447.9K | EDGAR |
| 2018-05-16 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +33,750 | $0 | EDGAR |
| 2018-02-22 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −4,741 | -$137.9K | EDGAR |
| 2018-02-14 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +9,000 | $0 | EDGAR |
| 2017-11-22 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −5,820 | -$166.3K | EDGAR |
| 2017-08-23 | Theravance Biopharma, Inc. (TBPH) Delisted | Buy (P) | +4,000 | $105.4K | EDGAR |
| 2017-08-22 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −5,820 | -$159.5K | EDGAR |
| 2017-05-23 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −5,820 | -$214.4K | EDGAR |
| 2017-02-22 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −8,762 | -$296.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.